rHuEPO and treatment outcomes: The clinical experience

Oncologist

Volumn 9, Issue SUPPL. 5, 2004, Pages 55-69

  Hudis, Clifford A ^a   Van Belle, Simon ^b   Chang, Jose ^c   Muenstedt, Karsten ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Durham Regional Cancer Centre   (Canada)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Anemia; Cancer; Epoetin alfa; Hemoglobin; Outcomes; Quality of life; rHuEPO; Survival; Tumor hypoxia

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME; UTERINE CERVIX CANCER; WALDENSTROEM MACROGLOBULINEMIA;

ACTIVITIES OF DAILY LIVING; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FATIGUE; HEMOGLOBINS; HUMANS; NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 10644226919     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90005-55     Document Type: Conference Paper

References (69)

1. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-2221.
2. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(suppl 8):49-53.
3. Harrison LB, Chadha M, Hill RJ et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. The Oncologist 2002;7:492-508.
4. Van Belle SJ, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11.
5. Henke M, Sindlinger F, Ikenberg H et al. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol 2004;180:45-51.
6. Muenstedt K. Hemoglobin concentration before chemotherapy is an independent prognostic factor in ovarian carcinomas. Proc Am Soc Clin Oncol 2002;21:216a.
7. Sevelda P, Gnant M, Lainz K. Influence of anemia on local relapse-free survival (LRFS) of premenopausal primary breast cancer patients under adjuvant CMF chemotherapy: an analysis of the Austrian Breast Cancer Study Group. Proc Am Soc Clin Oncol 2002;21:65a.
8. Morganti AG, Forni F, Macchia G et al. Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure. Strahlenther Onkol 2003;179:87-92.
9. Grogan M, Thomas GM, Melamed I et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.
10. Thomas G. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 2001;28(suppl 8):60-65.
11. Antonadou D, Cardamakis E, Puglisi M et al. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J Cancer 2001;37(suppl 6):S144.
12. Glaser CM, Millesi W, Kornek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.
13. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
14. Blohmer JU, von Minckwitz G, Paepke S et al. Sequential adjuvant chemo-radiotherapy with vs. without erythropoietin for patients with high-risk cervical cancer-second analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Proc Am Soc Clin Oncol 2002;21:206a.
15. Pangalis GA, Siakantaris MP, Angelopoulou MK et al. Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica 2002;87:500-506.
16. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
17. Littlewood T, Bajetta E, Rapoport B et al. Early administration of epoetin alfa optimizes anemia management with respect to hematologic and quality of life (QOL) outcomes in anemic cancer patients (pts) undergoing chemotherapy. Blood 2002;100:18b.
18. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(suppl2):13-19.
19. Langer C, Barsevick A, Bruner D et al. Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel. Lung Cancer 1997;18(suppl 1):23.
20. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
21. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
22. Cleeland CS, Demetri GD, Glaspy J et al. Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc Am Soc Clin Oncol 1999;18:574a.
23. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
24. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
25. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699.
26. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992;87(suppl 1):4-11.
27. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
28. Soignet S. Management of cancer-related anemia: epoetin alfa and quality of life. Semin Hematol 2000;37(suppl 6):9-13.
29. Demetri GD, Gabrilove JL, Blasi MV et al. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 2002;3:45-51.
30. Curt GA. The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. The Oncologist 2000;5(suppl 2):9-12.
31. Curt GA, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The Oncologist 2000;5:353-360.
32. Fallowfield L, Gagnon D, Zagari M et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002;87:1341-1353.
33. Shasha D, George M, Harrison L. Significant relationships between hemoglobin (Hb) levels and quality of life (QoL) during chemoradiation: findings from an incremental analysis of a 442-patient, prospective, community-based epoetin alfa study. Int J Radiat Oncol Biol Phys 2002;54(suppl 2):48.
34. Shasha D, George M, Harrison L. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Blood 2000;96:434a.
35. Patrick DL, Gagnon DD, Zagari MJ et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-345.
36. Cella D, Zagari MJ, Vandoros C et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366-373.
37. Chap L, George M, Glaspy J. Evaluation of epoetin alfa (Procrit) 60,000 U once weekly in anemic cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol 2002;21:264b.
38. Hudis C, Williams D, Gralow J. Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients during adjuvant chemotherapy. Proc Am Soc Clin Oncol 2002;21:380a.
39. Patton J. Camp M, Kuzur M et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Blood 2002:100:16b.
40. McKenzie S. Heifetz L. Duh M et al. Effectiveness of epoetin alfa beyond once-weekly dosing schedules in the oncology community practice setting. Blood 2002;100:501b.
41. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531.
42. Cerami A, Brines ML, Ghezzi P et al. Effects of epoetin alfa on the central nervous system. Semin Oncol 2001:28(suppl 8):66-70.
43. Farrell F. Lee A. The crythropoictin receptor and its expression in tumor cells and other tissues. The Oncologist 2004:9(suppl 5):18-30.
44. O'Shaughnessy J. Vukelja S, Savin M et al. Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data. Breast Cancer Res Treat 2002;76:S138.
45. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. BEST Investigators and Study Group. Lancet Oncol 2003;4:459-460.
46. Möbus VJ, Untch M, Du Bois A et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≤4 +LN). First results of an AGO-trial. Proc Am Soc Clin Oncol 2004;22:543a.
47. Albain KS, Crowley JJ,LeBlanc M et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
48. Ohlhauser C, Bulzebruck H, Ebert W et al. Prognostic factors for survival in inoperable non-small-cell lung cancer: a multivariate regression analysis of 456 patients with radiation therapy. Onkologie 1997;20:126-131.
49. Wilhelm R, Kovacs G, Heinrichsohn D et al. [Survival of exclusively irradiated patients with NSCLC. Significance of pretherapeutic hemoglobin level.] Strahlenther Onkol 1998;174:128-132. German.
50. Ylisirnio S, Sassi ML, Risteli J et al. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res 1999;19:5577-5581.
51. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-968.
52. Obermair A, Petru E, Windbichler G et al. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep 2000;7:639-644.
53. Obermair A, Cheuk R, Horwood K et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 2001;92:903-908.
54. Marinaccio M, Mele E, DeMarino E et al. Pretreatment serum hemoglobin as a prognostic factor in epithelial ovarian cancer. Proc Am Soc Clin Oncol 2002;21:216a.
55. Masuda H, Kurita Y. Fukuta K et al. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma, Int J Urol 1998;5:418-422.
56. Motzer RJ. Mazumdar M. Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540.
57. Sengelov L, Kamby C. Geertsen P et al. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol 2000;46:357-364.
58. Vollmer RT, Kantoff PW. Dawson NA et al. A prognostic-score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. Clin Cancer Res 1999;5:831-837.
59. Wagner W, Hermann R, Hartlapp J et al. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther Onkol 2000;176:73-80.
60. Moullet I, Salles G, Ketterer N et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998;9:1109-1115.
61. Federico M, Vitolo U. Zinzani PL et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo ltaliano Linfomi. Blood 2000;95:783-789.
62. Callea V, Clo V, Morabito F et al. Retrospective analysis of mantle cell lymphoma: experience of the "Gruppo ltaliano per lo Studio dei Linfomi" (GISL). Haematologica 1998;83:993-997.
63. Samaha H, Dumontet C, Ketterer N et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998;12:1281-1287.
64. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
65. Landman-Parker J, Pacquement H, Leblanc T et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000;18:1500-1507.
66. Liao Z, Ha CS, Fuller LM et al. Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys 1998;41:1047-1056.
67. Keating MJ, Smith TL, Lerner S et al. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma 2000;37:71-85.
68. Kern W, Schoch C, Haferlach T et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000;14:226-231.
69. Morel P, Monconduit M. Jacomy D et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000;96:852-858.